PACS IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PACS Group Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PACS

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of PACS Group Inc. (NYSE: PACS) of (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) in connection with the Company’s April 11, 2024 initial public offering (“IPO”); (ii) securities between April 11, 2024 and November 5, 2024, both dates inclusive (the “Class Period”); and/or (iii) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s September 2024 secondary public offering (“SPO”), of the important January 13, 2025 lead plaintiff deadline.

SO WHAT: If you purchased PACS common stock pursuant and/or traceable to the IPO and/or securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PACS class action, go to https://rosenlegal.com/submit–form/?case_id=30617 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) PACS engaged in a “scheme” to submit false Medicare claims which “drove more than 100% of PACS’ operating and net income from 2020 – 2023”; (2) PACS engaged in a “scheme” to “bill thousands of unnecessary respiratory and sensory integration therapies to Medicare”; (3) PACS engaged in a scheme to falsify documentation related to licensure and staffing; and (4) as a result of the foregoing, defendants’ positive statements about PACS’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PACS class action, go to https://rosenlegal.com/submit–form/?case_id=30617 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9323790)

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ASP Isotopes Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ASPI

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ASP Isotopes Inc. (NASDAQ: ASPI) between October 30, 2024 and November 26, 2024, both dates inclusive (the “Class Period”), of the important February 3, 2025 lead plaintiff deadline.

SO WHAT: If you purchased ASP Isotopes securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ASP Isotopes class action, go to https://rosenlegal.com/submit–form/?case_id=32062 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) ASP Isotopes overstated the potential effectiveness of its enrichment technology; (2) ASP Isotopes overstated the development potential of its high assay low–enriched uranium facility; (3) ASP Isotopes overstated ASP Isotopes’ nuclear fuels operating segment results; and (4) as a result of the foregoing, defendants’ positive statements about ASP Isotopes’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ASP Isotopes class action, go to https://rosenlegal.com/submit–form/?case_id=32062 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9323846)

Injonction préliminaire émise en faveur des sachets de nicotine 2ONE® contre les sachets Zone. Imperial se voit interdire toute vente future du produit [Zone] portant la marque Bullseye ou de toute imitation colorée ou marque d’un produit similaire portant à confusion et lié à la nicotine par voie orale

LAKE TAHOE, Nevada, 24 déc. 2024 (GLOBE NEWSWIRE) — 2ONE Labs et Performance Plus Marketing (« PPM ») ont obtenu une injonction préliminaire (« IP ») favorable dans le cadre du [...] Read more »

Injunção Preliminar Emitida em favor de 2ONE® Nicotine Pouches Contra Zone Pouches – Imperial proíbe o envolvimento da Zone em quaisquer vendas futuras do produto [Zone] com a Marca Bullseye ou qualquer imitação colorida ou marca confusamente semelhante ao produto ligado à nicotina oral

LAKE TAHOE, Nevada, Dec. 24, 2024 (GLOBE NEWSWIRE) — A 2ONE Labs e a Performance Plus Marketing ('PPM') receberam uma liminar favorável (‘PI‘) relativa à disputa de marca registrada em andamento [...] Read more »

Einstweilige Verfügung zugunsten von 2ONE® Nicotine Pouches gegen Zone Pouches – Imperial wird untersagt, in Zukunft das [Zone]-Produkt mit dem Bullseye-Zeichen oder ein farblich ähnliches Produkt oder ein Produkt mit einem verwechselbar ähnlichen Zeichen, das mit oralem Nikotin in Verbindung steht, zu verkaufen.

LAKE TAHOE, Nevada, Dec. 24, 2024 (GLOBE NEWSWIRE) — 2ONE Labs und Performance Plus Marketing („PPM“) haben eine positive einstweilige Verfügung (Preliminary Injunction, „PI“) im Zusammenhang mit dem [...] Read more »

Preliminary Injunction Issued in favor of 2ONE® Nicotine Pouches Against Zone Pouches – Imperial are enjoined from engaging in any future sales of the [Zone] product bearing the Bullseye Mark or any colorable imitation or mark confusingly similar product connected with oral nicotine

LAKE TAHOE, Nev., Dec. 23, 2024 (GLOBE NEWSWIRE) — 2ONE Labs and Performance Plus Marketing ('PPM') have been granted a favorable Preliminary Injunction (‘PI’) Order relating to the ongoing trademark dispute [...] Read more »